Pharma and healthcare: sector news on Tuesday 17 November 2026
Average tone +5.6 (positive) across 4 companies with relevant coverage, from 57 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +9.7 | 45 | Coverage was led by a string of regulatory successes, chiefly US and EU clearance for Klygefa, the myasthenia gravis treatment, US clearance for Imfinzi in bladder cancer and a European recommendation for the blood pressure drug Baxfendy. |
| GSK | +5.7 | 8 | Coverage leaned positive, driven by a European regulator committee backing wider use of ViiV's HIV drugs, a licensing deal and a broker raising its long-term revenue forecast. |
| Convatec | +5.0 | 2 | Coverage was light, led by a report that the shares are trading close to their 52-week high, which leans positive. |
| Smith & Nephew | +2.0 | 2 | Coverage was light, with a share price note showing the stock little changed and a commentary piece asking whether it could stand out as investors rotate. |
| Haleon | — | 0 |
Strongest stories in the sector
- +10.0 Four regulatory successes across several areas.
- +10.0 Two US regulatory clearances for new uses and a new drug.
- +10.0 US clearance for broader use of cancer drug and new therapy.
- +10.0 New drug cleared in both US and Europe.
- +10.0 Several approvals covering bladder cancer and a rare disease.
- +10.0 Next-generation therapy cleared in both markets.
- +10.0 American regulator clears new generalised myasthenia treatment.
- +10.0 Rare muscle disorder drug cleared in two regions.
- +10.0 Self-administered therapy cleared in US and Europe.
- +10.0 European clearance for myasthenia treatment.
- +10.0 Approvals secured on both sides of Atlantic.
- +10.0 US clearance for bladder cancer combination.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.